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RSH/Smith-Lemli-Opitz Syndrome: Mutations and Metabolic
Morphogenesis
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For almost 30 years following its description in 1964,
the RSH syndrome—now more often called the “Smith-
Lemli-Opitz syndrome” (SLOS)—was just one of many
autosomal recessive, multiple anomaly syndromes that
filled the pages of dysmorphology atlases (MIM 270400;
Smith et al. 1964). Its specific combination of craniofa-
cial anomalies, polydactyly, cleft palate, and genital mal-
formations in males was readily diagnosed by dysmor-
phologists but otherwise caused little interest. In 1993,
however, SLOS was abruptly lifted from relative obscu-
rity by the discovery that affected patients have as much
as 2,000-fold–increased blood levels of 7–dehydrocho-
lesterol (7DHC), the immediate precursor of cholesterol
in the Kandutsch-Russell pathway of cholesterol bio-
synthesis (Irons et al. 1993; Tint et al. 1994). The now
apparent high specificity of increased 7DHC levels for
diagnosis of SLOS (Cunniff et al. 1997) has made pos-
sible not only definitive diagnosis of SLOS but also pre-
natal diagnosis by measurement of 7DHC in amniotic
fluid or chorionic villus (Abuelo et al. 1995; Rossiter et
al. 1995; Mills et al. 1996). Not unexpectedly, the avail-
ability of a laboratory test for SLOS also has led to an
expansion of its clinical phenotype to include near-nor-
mal children with no discrete malformations, as well as
severely malformed fetuses that die in utero. Studies of
blood sterol levels of SLOS patients show that clinical
severity correlates best not with the absolute level of
7DHC but inversely either with the level of cholesterol
or with the level of cholesterol as a fraction of total
sterols (Cunniff et al. 1997). The most severely affected,
“type II” SLOS patients (Curry et al. 1987) typically
have blood cholesterol levels of 1–10 mg/dl (0.03–0.3
mmol/liter) and die in the newborn period because of
multiple internal anomalies (Tint et al. 1995). At the
other extreme, ∼10% of SLOS patients have minimal
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disease and normal or low-normal cholesterol levels at
diagnosis (Cunniff et al. 1997). Although, historically,
a clinical distinction often was made between classic
(“type I”) SLOS and the more severe, type II patients,
there is, in reality, a clinical and biochemical continuum
from mild to severe SLOS (Cunniff et al. 1997).
Cholesterol Biosynthesis and 3b-Hydroxysterol-D7-
Reductase
The biosynthesis of cholesterol and its related family
of “isoprenoid” compounds, including coenzyme Q and
dolichols, begins with the conversion of 3-hydroxy-3-
methylglutaric acid to mevalonic acid and progresses to
the synthesis of polyisoprenoids, such as geraniol-PP and
farnesol-PP. After the formation of the first sterol, lan-
osterol, from squalene, there follows a succession of de-
methylations and double-bond rearrangements, the last
of which is the reduction of the 7-8 double bond of
7DHC to form cholesterol, mediated by the microsom-
al enzyme, 3b-hydroxysterol-D7-reductase (DHCR7;
E.C.1.3.1.21). The finding of marked elevations of
7DHC in SLOS immediately implicated DHCR7 as the
site of the genetic defect (Tint et al. 1994). Although the
chromosomal location of DHCR7 was unknown in
1993, attention soon turned to 7q32.1 because of two
unrelated SLOS patients, one of whom was biochemi-
cally confirmed, who were found to have translocations
at that position (Alley et al. 1995). However, earlier this
year, Fabian Moebius and colleagues reported the clon-
ing of a human microsomal DHCR7 gene and mapped
it to chromosomal position 11q12-13 (Moebius et al.
1998). The same laboratory has now reported that all
13 patients with classical SLOS whom they studied had
mutations in DHCR7 (Fitzky et al. 1998). In this and
the July issue of the Journal, two other groups working
independently, one at the National Institutes of Health
and headed by Forbes Porter and another that is a con-
sortium of Dutch centers, report mutations of the same
DHCR7 gene in six additional patients with SLOS (Was-
siff et al. 1998; Waterham et al. 1998), confirming that,
for most patients with a clinical diagnosis of SLOS and
increased 7DHC levels, the gene for DHCR7 harbors
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the responsible mutations. However, because one pair
of siblings with phenotypic SLOS and moderately in-
creased levels of 7DHC has been found to have an ap-
parent defect of sterol transport (Anderson et al. 1998),
mutations in genes other than DHCR7 are possible.
The three articles describingDHCR7mutations reveal
interesting aspects of the biochemistry and population
genetics of SLOS. The historically relatively high inci-
dence of SLOS—∼1/20,000–30,000 births among those
of northern- and central-European background (Opitz
1994; Cunniff et al. 1997)—suggests either heterozygote
advantage or one or more founder mutations. Possibly,
both mechanisms are involved. Of 19 different DHCR7
mutations found in, coincidentally, 19 patients, there
were 13 missense mutations, 1 nonsense mutation, and
5 frameshift mutations. Of these mutations, three oc-
curred in four or more patients, the most interesting
being a 134-bp insertion found in 7 of 38 alleles. This
particular mutation is predicted to abolish all DHCR7
activity and was homozygous in 2 of the 19 patients
studied, both of whom had a diagnosis of type II SLOS.
Because the most severely affected patients have meas-
urable cholesterol levels at birth, typically 5–10 mg/dl
(Tint et al. 1995; Cunniff et al. 1997), there may be
another genetic source of DHCR7 activity. Alternatively,
there could be either a pathway of cholesterol synthesis
not requiring DHCR7 or more maternal-to-fetal transfer
of cholesterol than currently is thought. The finding of
many different DHCR7 mutations in this relatively com-
mon malformation syndrome suggests a heterozygote
advantage, such as increased production of vitamin D
from the mildly increased plasma levels of 7DHC in
SLOS parents (Opitz and de la Cruz 1994; Kelley 1995).
The diversity of DHCR7 mutations also means that mea-
surement of plasma and tissue sterol levels will remain
the primary method for diagnosis of SLOS. However,
mutational analysis may be useful in the evaluation of
suspected SLOS patients with normal or equivocally in-
creased 7DHC levels.
SLOS, Holoprosencephaly (HPE), and the Metabolism
of Morphogenesis
As work progressed on the molecular and biochemical
characterization of SLOS, major advances also were be-
ing made in the study of HPE and the “hedgehog” class
of embryonic signaling proteins, two areas of genetics
at first seemingly unrelated to SLOS. However, these
three areas of research now have converged in a re-
markable way that provides new insights into human
morphogenesis. This part of the SLOS story actually
begins before the first clinical description of SLOS when,
in the early 1960s, researchers discovered that inhibitors
of enzymes of the distal cholesterol biosynthetic path-
way, including DHCR7, caused HPE, pituitary agenesis,
and, less frequently, limb and genital anomalies in the
pups of pregnant rats or mice (Roux and Aubry 1966;
Roux et al. 1980). An even more convincing SLOS phe-
notype recently has been produced by treatment of preg-
nant, cholesterol-deficient mice with an inhibitor of
DHCR7 (Lanoue et al. 1997). HPE, a failure of normal
bilobar development of the forebrain and a prominent
characteristic of all animal models of fetal exposure to
inhibitors of DHCR7, was reported in only one SLOS
patient prior to 1993 (McKeever and Young 1990).
However, by use of an increased 7DHC level as a di-
agnostic biochemical marker, SLOS now has been iden-
tified in at least seven patients with HPE (Kelley et al.
1996; author’s unpublished data). Although all of these
HPE patients had other physical characteristics of SLOS,
in most of them the diagnosis of SLOS could not have
been made without measurement of plasma sterols, be-
cause the facial anomalies associated with HPE, such as
midline cleft lip and hypotelorism, obscured the diag-
nostically important facial dysmorphism of SLOS.
At the same time that dysmorphologists were dusting
off their biochemistry books to study cholesterol me-
tabolism, Jeffery Porter, Phil Beachy, and their colleagues
at Johns Hopkins made the startling discovery that co-
valent addition of cholesterol to Sonic hedgehog (Shh),
an embryonic signaling protein, was an essential part of
Shh’s “autoprocessing” reaction (Porter et al. 1995,
1996b). In this reaction, precursor Shh protein in the
presence of cholesterol cleaves itself to form a nonsig-
naling COOH-terminal half and a mature, cholesterol-
substituted, N-terminal half, “Shh-N.” Shh-N appears
to possess all Shh signaling activity, which in vertebrates
includes patterning of development in the ventral fore-
brain and limb buds, among other structures. Although
the covalently attached cholesterol moiety is not essential
for intrinsic signaling activity of Shh–N, it appears to
have a role in the attachment and localization of Shh-
N to cell membranes (Porter et al. 1996a).
The first link between Shh and HPE was made when
Chiang et al. (1996) reported that homozygous Shh
knockout mice developed HPE. This discovery soon was
followed by the report that mutations in SHH, the 7q36-
linked gene encoding SHH in humans, caused autosomal
dominant HPE (Roessler et al. 1996). The possibility
that cholesterol might play an important role in embry-
onic forebrain development had been suggested some-
what earlier by the discovery that transgenic mice de-
ficient in the synthesis of megalin (Willnow et al. 1996),
an important component of a system for delivery of ma-
ternal LDL cholesterol to the embryonic neuroepithel-
ium, also develop HPE. Possibly related CNS malfor-
mations also were found in transgenic mice lacking
apolipoprotein B, another component of the embryonic
cholesterol-delivery system (Farese et al. 1995). This un-
expected convergence of HPE, SLOS, Shh, and choles-
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terol metabolism immediately focused attention on the
possibility that the covalent attachment of cholesterol to
Shh-N and related hedgehog proteins is the link between
the abnormal cholesterol metabolism of SLOS and ab-
normal morphogenesis of SLOS.
Like many other wonderful unitary theories that pre-
ceded it, the proposal that abnormalities of cholesterol-
mediated Hedgehog autoprocessing causes HPE and
other malformations is probably wrong. The story is
indeed much more complex. Addressing the relationship
between Shh function and abnormal cholesterol metab-
olism, Michael Cooper, Phil Beachy, and coworkers
(Cooper et al. 1998) have shown that autoprocessing of
Hedgehog is not impaired when cholesterol in the re-
action medium is replaced by 7DHC or any of many
other 27-carbon sterols tested. Although the possibility
that 7DHC-modified Shh-N might not have normal sig-
naling function was not assessed directly, additional in
vitro studies with AY-9944 (which produces SLOS-like
sterol abnormalities) and teratogens that cause SLOS-
like malformations in rats strongly suggested that the
defect in Shh signaling resided in the target tissue and
not in the Shh-N signal itself. For example, treatment
of target tissue (chick neural-plate ectoderm) for 48 h
with AY-9944, Triparanol, or jervine at concentrations
that produce HPE in whole chick embryos completely
blocked signaling by recombinant Shh-N (Cooper et al.
1998). Moreover, studies in my laboratory suggest that
it is not just impaired cholesterol biosynthesis in the
target tissue that limits Shh signaling. For example,
whereas both AY-9944 and the plant alkaloid tomatidine
cause severe impairment of cholesterol biosynthesis and
marked increases in 7DHC in cultured cells and chick
embryos, only AY-9944 is teratogenic and blocks Shh
signaling (author’s unpublished observations). However,
as shown by Cooper et al. (1998), all of the known
synthetic and plant teratogens that cause HPE also im-
pair intracellular cholesterol transport, as measured by
uptake and esterification of extracellular cholesterol.
One possible target of teratogen-induced abnormal in-
tracellular cholesterol metabolism is “Patched,” a pu-
tative hedgehog receptor (Ingham et al. 1991; Stone et
al. 1996; Goodrich et al. 1997) that contains a sterol-
sensing domain (Stone et al. 1996).
Shh is just one of several similarly functioning hedge-
hog proteins, all of which may interact with Patched in
a sterol-sensitive manner. Thus, it is possible that im-
paired signaling activities of other hedgehog proteins,
such as Desert hedgehog (Bitgood et al. 1996) and Indian
hedgehog (Iwasaki et al. 1997), also play a role in the
abnormal morphogenesis of SLOS tissues that are not
targets of Shh signaling. For example, although steroid
abnormalities often are presumed to be the cause of the
hypogenitalism of SLOS, the persistence of Mu¨llerian
remnants in some severely affected SLOS males (Bialer
et al. 1987) could be explained by inadequate signaling
of Desert Hedgehog, which is prominently expressed in
Sertoli cells, the source of Mu¨llerian inhibitory factor
(Bitgood et al. 1996). Despite the attractiveness of and
experimental support for the role of impaired Hedgehog
signaling in SLOS morphogenesis, other, less-specific dis-
turbances also could be involved. In several 10–20-wk
SLOS fetuses tested in my laboratory, cholesterol is se-
verely deficient in all tissues, with 7DHC and related
cholesterol precursors typically constituting x75% of
fetal sterols. Such a severe disturbance in membrane
sterol composition is likely to affect many critical de-
velopmental processes that involve cell-cell interactions,
as suggested by Sulik and colleagues in their recent stud-
ies with the SLOS-mimicking teratogen, BM 15,776 (De-
hart et al. 1997). Even in tissue culture, SLOS fibroblasts
interact abnormally with themselves and with the
growth surface (author’s unpublished observations).
Future Directions
Where do all these remarkable findings leave our
SLOS patients and their families? What clinical benefit
can be derived from these discoveries? What other syn-
dromes are likely to involve abnormalities of cholesterol
metabolism or Hedgehog proteins?
Although most geneticists interested in SLOS are
learning more about cholesterol metabolism and Sonic
hedgehog than they ever imagined, the most important
changes are in the homes of the SLOS children. A reading
of any issue of the newsletter of the RSH/Smith-Lemli-
Opitz Advocacy and Exchange, the family support group
for SLOS, will show how profoundly some SLOS chil-
dren and adults are affected when their cholesterol-de-
ficiency syndrome finally is treated. Growth improves,
older children learn to walk, and adults speak for the
first time in years. Equally important is how much better
the children feel. Sometimes after just days or weeks of
cholesterol treatment, head banging stops, agitation
passes to calm, and older children and adults verbalize
how much better they feel. As we become more involved
in the treatment of SLOS patients, it is also important
to note that DHCR7 first was cloned not as the SLOS
gene but as the gene for a promiscuous drug-binding
protein (Moebius et al. 1997, 1998). We should remem-
ber this fact not only in evaluating the behavioral phar-
macology of SLOS but also in considering DHCR7 and
cholesterol biosynthesis as potentially significant ancil-
lary sites of action of various drugs in any patient.
The discovery of mutations of DHCR7 as the cause
of SLOS will lead to the inevitable DHCR7 knockout
mouse and, we hope, to animal models of different ther-
apy modalities. Mutational analysis will allow more-
accurate carrier testing as well as preimplantation test-
ing. In the meantime, work on various aspects of sterol
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metabolism in SLOS continues. An earlier observation
now under active reinvestigation is that mothers carrying
SLOS fetuses have much lower than normal levels of
serum unconjugated estriol (McKeever and Young
1990). If confirmed as a consistent marker for SLOS,
the finding of a low maternal serum estriol level may
allow detection of this relatively common disorder in
families without a known risk for SLOS. Another im-
portant clinical question to be answered is whether dif-
ferences in human maternal cholesterol levels influence
the delivery of cholesterol to the developing embryo, as
some studies of AY-9944 in rats have suggested (Barbu
et al. 1984).
Finally, the new molecular embryology of SLOS and
its connection with HPE and, possibly, with Shh already
has spawned a small industry of sterol teratology. Dys-
morphologists naturally will look at other biochemically
undiagnosed malformation syndromes and wonder
whether therein lurk new disorders of cholesterol bio-
synthesis. Indeed, an apparent defect in desmosterol (24-
dehydrocholesterol) metabolism already has been
described in a single stillborn infant with some char-
acteristics of SLOS (FitzPatrick et al. 1998). However,
SLOS as a “metabolic malformation” syndrome may be
the exception rather than the rule. In this era of weekly
discoveries of new genes for old syndromes, most mu-
tations that cause multiple congenital malforma-
tion syndromes—that is, disturbances of the body
plan—have not been disorders of intermediary metab-
olism but, instead, mutations of homeobox genes and
other transcriptional regulators and signaling systems.
Even the widespread and severe biochemical distur-
bances of a classic prenatal metabolic disorder such as
Zellweger syndrome have few effects on the body plan.
Thus, SLOS and possibly a few other sterol defects may
be exceptional, because their abnormal sterol biochem-
istry, which cannot be corrected by maternal sources,
appears to disrupt the action of Hedgehog proteins, im-
portant embryonic proteins with diverse effects on the
activity of transcriptional regulators. Nevertheless, be-
cause clinical screening for abnormal cholesterol bio-
synthesis was unknown before the discovery of increased
7DHC levels in SLOS, we should remind ourselves as
we see our patients with unexplained syndromes that
there are many other categories of obligate fetal metab-
olite biosynthesis for which no systematic metabolic
screening exists and for which no genetic defects are
known.
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